These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 38614231)
1. Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era. Vergori A; Cozzi Lepri A; Chiuchiarelli M; Mazzotta V; Metafuni E; Matusali G; Siciliano V; Paulicelli J; Alma E; Siniscalchi A; Sica S; Abruzzese E; Fantoni M; Antinori A; Cingolani A Int J Infect Dis; 2024 Jul; 144():107042. PubMed ID: 38614231 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis. Demolder S; Schaevers V; Lagrou K; De Munter P; Beeckmans H; Verleden GM; Godinas L; Dupont LJ; Van Bleyenbergh P; Lorent N; Vos R Transpl Int; 2024; 37():12061. PubMed ID: 38328617 [TBL] [Abstract][Full Text] [Related]
5. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants? Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720 [TBL] [Abstract][Full Text] [Related]
6. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases. Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774 [TBL] [Abstract][Full Text] [Related]
7. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data. Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398 [TBL] [Abstract][Full Text] [Related]
8. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients. Laracy JC; Yan J; Steiger SN; Tan CA; Cohen N; Robilotti EV; Fender J; Cohen S; Korde N; Lee-Teh M; Noy A; Oved JH; Roeker LE; Shah G; Babady NE; Kamboj M; Seo SK Haematologica; 2023 Nov; 108(11):3058-3067. PubMed ID: 37345467 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study. Simone S; Pronzo V; Pesce F; Bavaro DF; Infante B; Mercuri S; Schirinzi A; Panaro A; Conte E; Belati A; Troise D; Pontrelli P; Conserva F; Gallo P; Panico M; Spilotros M; Lucarelli G; Saracino A; Stallone G; Di Serio F; Ditonno P; Gesualdo L J Nephrol; 2024 Jul; 37(6):1539-1550. PubMed ID: 38780697 [TBL] [Abstract][Full Text] [Related]
10. Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study. Vergori A; Matusali G; Cimini E; Bordi L; Borrelli P; Lanini S; Palazzi R; Paulicelli J; Mariotti D; Mazzotta V; Notari S; Casetti R; Francalancia M; Rosati S; D'Abramo A; Mija C; Mencarini P; Milozzi E; Caraffa E; Sica S; Metafuni E; Sorà F; Rago A; Siniscalchi A; Abruzzese E; Garzia M; Luzi G; Battistini R; Prosperini L; Cingolani A; Girardi E; Maggi F; Antinori A; Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066422 [No Abstract] [Full Text] [Related]
11. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study. Basoulis D; Mastrogianni E; Karamanakos G; Gkoufa A; Georgakopoulou VE; Makrodimitri S; Gamaletsou MN; Markogiannakis A; Sipsas NV Viruses; 2024 Aug; 16(8):. PubMed ID: 39205319 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era. Gottlieb J; Simon S; Barton J; Barnikel M; Bachmann M; Klingenberg MS; Veit T; Kneidinger N Infection; 2023 Oct; 51(5):1481-1489. PubMed ID: 36929650 [TBL] [Abstract][Full Text] [Related]
14. Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation. Falcone M; Tiseo G; Marchetti G; Kalo J; Galfo V; Occhineri S; Almerigogna F; Matucci T; Riccardi N; Suardi LR; Rina I; Sijoni L; Caparello MC; Cassano Cassano R; Del Giudice ML; Franciosa M; Facella F; Tancredi G; Fazzi R; Galimberti S Leuk Lymphoma; 2024 Oct; 65(10):1474-1481. PubMed ID: 38832710 [TBL] [Abstract][Full Text] [Related]
15. Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab. Aihara R; Umemura K; Katada Y; Nakagawa S; Kobayashi T; Hatano E; Date H; Nagao M; Terada T J Infect Chemother; 2024 Dec; 30(12):1222-1227. PubMed ID: 38777151 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience. Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions. Duminuco A; Nardo A; Orofino A; Giunta G; Conticello C; Del Fabro V; Chiarenza A; Parisi MS; Figuera A; Leotta S; Milone G; Cupri A; Cambria D; Di Raimondo F; Romano A; Palumbo GA Cancer; 2024 Jan; 130(1):41-50. PubMed ID: 37658645 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients. Marti-Pastor M; Bou-Monterde R; Ciancotti-Oliver L; Alcover-Pons M; Amorós Cantero A; Sánchez-Lopezosa R; Montañana-Rosell N Med Clin (Barc); 2024 Sep; 163(6):275-280. PubMed ID: 38937218 [TBL] [Abstract][Full Text] [Related]
19. [Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies]. Roppelt AA; Lebedkina MS; Chernov AA; Kruglova TS; Mukhina OA; Yukhnovskaya YD; Samedova FA; Mаrkina UA; Andrenova GV; Karaulov AV; Lysenko MA; Fomina DS Ter Arkh; 2023 Feb; 95(1):78-84. PubMed ID: 37167118 [TBL] [Abstract][Full Text] [Related]
20. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis. Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]